SecBot SecBot
8-K ·Filed May 14, 2026

SGP

SpyGlass Pharma, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed6mo ago SEC0001778922-26-000033
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

No material surprise vs expectations, the stock will trade on Phase 3 enrollment updates and BIM-DRS FIH trial initiation in H2 2026. Monitor for any enrollment delays or safety signals in the ongoing registrational trials.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$23.21
T+0 close · May 14, 2026 · via day close
Latest settled
+7.07%
T+60 · $24.85
Vs SPY
+2.55%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 15 $23.21entry
  2. T+1 · 6mo ago −4.18%α −4.12% · $22.24
  3. T+5 · 6mo ago −10.21%α −11.17% · $20.84
  4. T+20 · 5mo ago −20.55%α −22.67% · $18.44
  5. T+60 · 3mo ago +7.07%α +2.55% · $24.85

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

SpyGlass Pharma reported Q1 2026 net loss of $13.8M ($-0.69/share), in line with the $-0.67 consensus estimate. The company highlighted $251M cash runway through 2028 and on-track Phase 3 enrollment for its BIM-IOL System, with BIM-DRS FIH trial expected in H2 2026. This is a pre-revenue clinical-stage biotech filing with no revenue to report, the focus is on pipeline execution and cash position.

Key Financial Metrics

EPS
−$0.69
est −$0.67 · -3.0%
Rating
in line

Key Facts

  • Q1 2026 net loss of $13.8M, or ($0.69) per basic/diluted share, vs consensus estimate of ($0.67)
  • Cash, cash equivalents and short-term investments of $251.0M as of March 31, 2026, expected to fund operations through 2028
  • Phase 3 trials (SGP-005 and SGP-006) enrollment on track with completion expected in 2027
  • BIM-DRS first-in-human trial on track to start in H2 2026
  • No revenue reported, pre-revenue clinical-stage company
  • R&D expenses $8.5M (up from $6.1M YoY); G&A expenses $6.9M (up from $1.4M YoY) due to clinical hiring and public company costs
  • IPO in February 2026 raised $172.5M in gross proceeds

Financial Impact

Net loss of $13.8M in Q1 2026, in line with consensus of ($0.67) per share; cash position $251M provides runway through 2028

net losscash positionR&D spend

Risk Factors

  • Clinical trial enrollment delays or failure in Phase 3 BIM-IOL trials
  • Cash burn rate may accelerate if trials expand or take longer than expected
  • Regulatory risk, FDA approval not guaranteed for BIM-IOL System
  • Competition from existing glaucoma treatments and other drug delivery platforms

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001778922-26-000033
Document: sgp-20260514.htm0001778922-26-000033
Document: 0001778922-26-000033-index-headers.html0001778922-26-000033
Document: 0001778922-26-000033-index.html0001778922-26-000033
Document: 0001778922-26-000033.txt0001778922-26-000033
8-K Data (Synthetic)0001778922-26-000033

Track record

9 reports on SGP

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +33.66% at T+20 after the Oct 19, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 12, 20264d ago 8-K Neutral 4/10 No price data
  2. Nov 11, 20265d ago Press Release Neutral 4/10 Entry $33.32 Now $32.24 −3.24% settles Dec 11
  3. Oct 19, 202628d ago 8-K Bullish 6/10 Entry $26.16 Now $32.24 +23.24% settles Nov 17
  4. Oct 19, 202628d ago Press Release Bullish 7/10 Entry $24.60 to $32.88 Now $32.24 +31.06% ▲ +33.66% +37.12% vs SPY
  5. Oct 1, 20266w ago 8-K Bullish 6/10 Entry $26.50 to $32.51 Now $32.24 +21.66% ▲ +22.68% +21.98% vs SPY
  6. Oct 1, 20266w ago Press Release Bullish 6/10 Entry $26.50 to $32.51 Now $32.24 +21.66% ▲ +22.68% +21.98% vs SPY
  7. May 14, 202626w ago 8-K Neutral 4/10 Viewing Entry $23.21 to $18.44 Now $32.24 +38.91% ▼ −20.55% −22.67% vs SPY
  8. Mar 26, 202633w ago Press Release Bullish 8/10 Entry $22.61 to $23.65 Now $32.24 +42.59% ▲ +4.60% −8.14% vs SPY
  9. Mar 9, 202636w ago Press Release Bullish 8/10 Entry $27.12 to $21.07 Now $32.24 +18.88% ▼ −22.31% −19.50% vs SPY
Showing 9 of 9

US Market Status

Market Closed · Opens Wed (10h 3m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026